Abstract
Introduction
Most episodes of recurrent herpes labialis are self-limited and mild, but can be troublesome when they occur frequently with painful and unsightly lesions. Therefore, there has been much interest in developing agents that can suppress outbreaks in addition to being therapeutically effective. The objective of the present study was to examine the prophylactic and therapeutic efficacy of 1,5-pentanediol (PD) gel in patients with recurrent episodes of herpes labialis.
Methods
In this placebo-controlled, randomized, double-blind clinical trial, a total of 105 patients with frequent episodes of recurrent herpes were randomized to either PD or placebo. During the 26-week prophylactic phase of the study, the patients applied PD gel or placebo gel twice daily to both lips. Upon recurrence of an episode, a 5-day therapy phase started during which the gel was to be applied eight times daily. After the therapy phase, the patient resumed prophylactic treatment twice daily until the next herpes episode. The main outcome measures were number of herpes episodes during the prophylactic phase of 26 weeks, and successful therapy of occurring herpes episodes with a 5-day treatment.
Results
There was no significant difference in recurrence rate between the two groups (P>0.05). During recurrence there was a statistically significant improvement regarding the therapeutic effect of the symptoms “blistering,” “swelling,” and “pain” in the PD group. The global evaluation of efficacy by the investigators and patients showed a statistically significant superiority for PD as opposed to placebo (P<0.001).
Conclusion
Under the conditions used in the present study, PD did not show any prophylactic effect against recurrence of herpes episodes. A significantly better therapeutic effect of PD over placebo could be demonstrated on the symptoms “blistering,” “swelling,” and “pain.” PD was very safe as no side effects were observed during the course of the study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Siegel MA. Diagnosis and management of recurrent herpes simplex infections. J Am Dent Assoc. 2002;133:1245–1249.
Fatahzadeh M, Schwartz. Human herpes simplex labialis. Clin Exp Dermatol. 2007;32:625–630.
Lorette G, Crochar A, Mimaud V, Wolkenstein P, Stalder JF, El Hasnoui A. A survey on the prevalence of orofacial herpes in France: the INSTANT study. J Am Acad Dermatol. 2006;55:225–232.
Woo S-B, Challacombe SJ. Management of recurrent oral herpes simplex infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(suppl. 1):S12.e1–18.
Löwhagen GB, Bonde E, Eriksson B, Nordin P, Tunbäck P, Krantz I. Self-reported herpes labialis in a Swedish population. Scand J Infect Dis. 2002;34:664–667.
Malvy D, Ezzedine K, Lancon F, et al. Epidemiology of orofacial herpes simplex virus infection in the general population in France: results of the HERPIMAX study. Eur Acad Dermatol Venereol. 2007;21:1398–1403.
Raborn GW, Martel AY, Lassonde M, Lewis MAO, Boon R, Spruance SL. Effective treatment of herpes simplex labialis with penciclovir. Combined results of two trials. J Am Dent Assoc. 2002;133:303–309.
Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother. 2002;46:2238–2243.
Spruance SL, Rea TL, Thoming C, Tucker R, Salzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA. 1997;277:1374–1379.
Moomaw MD, Cornea P, Rathbun RC, Wendel KA. Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster. Expert Rev Anti Infect Ther. 2003;1:283–295.
Gibson JR, Klaber MR, Harvey SG, Tosti A, Jones D, Yeo JM. Prophylaxis against herpes labialis with acyclovir cream-a placebo-controlled study. Dermatologica. 1986;172:104–107.
Leung DT, Sacks SL. Docosanol: a topical antiviral for herpes labialis. Expert Opin Pharmacother. 2004;5:2567–2571.
Pope LE, Marcelletti JF, Katz LR, Katz DH. Antiherpes simplex virus activity of n-docosanol correlates with intracellular metabolic conversion of the drug. J Lipid Res. 1996;37:2167–2178.
Pope LE, Marcelletti JF, Katz LR, et al. The antiherpes simplex activity of n-docosanol includes inhibition of the viral entry process. Antiviral Res. 1998;40:85–94.
Faergeman J, Hedner T, Larsson P. The in vitro activity of pentane-1,5-diol against aerobic bacteria. A new antimicrobial agent for topical use? Acta Derm Venereol. 2005;85:203–205.
Jacobsson Sundberg J, Faergemann J. A comparison of pentane-1,5-diol to other diols for use in dermatology. Expert Opin Invest Drugs. 2008;17:601–610.
Al-Waili NS. Topical honey application vs. acyclovir for the treatment of recurrent herpes simplex lesions. Med Sci Monit. 2004;10:MT94–MT98.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Busch, R., Graubaum, HJ., Gruenwald, J. et al. Therapeutic effect of 1,5-pentanediol for herpes simplex labialis: a randomized, double-blind, placebo-controlled clinical trial. Adv Therapy 26, 719–727 (2009). https://doi.org/10.1007/s12325-009-0049-y
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-009-0049-y